Seven Tree Equity Partners
Overview
Seven Tree Equity Partners is a private equity firm that focuses on investing in high potential biotech and healthcare companies across the globe.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Elisigen | Jun 2021 | Series B | Co-investor |
| Neuracle Science | Jun 2019 | Series C | Co-investor |
| PeproMene Bio | Jun 2018 | Series B | Co-investor |
| ExoCoBio | Sep 2018 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Seven Tree Equity Partners based?
Seven Tree Equity Partners is headquartered in Seoul, South Korea.
When was Seven Tree Equity Partners founded?
Seven Tree Equity Partners was founded in 2018.
How many portfolio companies does Seven Tree Equity Partners have?
Seven Tree Equity Partners has 5 portfolio companies in Caplight's dataset.
What are some companies in Seven Tree Equity Partners's portfolio?
Portfolio companies visible on Caplight include Elisigen, Neuracle Science, PeproMene Bio, ExoCoBio.
What was Seven Tree Equity Partners's most recent investment shown here?
Seven Tree Equity Partners's most recent investment in this portfolio sample was in Elisigen in 2021.
What sectors does Seven Tree Equity Partners focus on?
Seven Tree Equity Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, Consumer & Commerce.
What company stages does Seven Tree Equity Partners focus on?
Seven Tree Equity Partners typically invests at the Mid stage.
What is Seven Tree Equity Partners's AUM?
Seven Tree Equity Partners's assets under management are estimated between $61.0M and $61.0M.